Emmanuel Hanon, Vicebio CEO (PRNewswire/Viome)

One year af­ter leav­ing GSK, Em­manuel Hanon jumps to Medicxi-backed vac­cine start­up with an eye on RSV

Af­ter 20 years of ser­vice at GSK — lead­ing glob­al vac­cines R&D for the last sev­en — Em­manuel Hanon left last year for a well­ness com­pa­ny with a gut mi­cro­bio­me fo­cus called Viome.

One of the ma­jor rea­sons for the de­par­ture, ac­cord­ing to him, was in essence to learn some­thing new and to be ex­posed to a new en­vi­ron­ment.

But it didn’t take long for him to re­turn to the vac­cine world full-time. Hanon has now tak­en the top po­si­tion at a Medicxi-backed biotech work­ing on a vac­cine for RSV called Vice­bio.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters